ARA 290 (Cibinetide) and Neuropathy: What the Research Actually Shows

Educational information only. ARA 290 is an investigational peptide and is not FDA-approved to treat any condition. This post is not medical advice.

If you live with nerve pain, burning, tingling, or numbness in your feet and hands, you know how stubborn neuropathy can be. Most standard treatments, like gabapentin, duloxetine, and topical agents, manage symptoms but do little to repair damaged nerves. That gap is why a peptide called ARA 290 has drawn so much attention.

What Is ARA 290?

ARA 290, also known as cibinetide, is a short peptide made of 11 amino acids. It was designed from a portion of erythropoietin (EPO), the hormone best known for stimulating red blood cell production. The key difference is that ARA 290 was engineered to keep EPO's tissue-protective effects without its effect on red blood cells, so it does not thicken the blood or raise hematocrit the way EPO does.

How Might It Help Nerves?

ARA 290 is thought to work through the innate repair receptor, a receptor complex that the body switches on in response to injury and inflammation. Researchers believe activating it may:

• Calm inflammation around damaged tissue and nerve fibers

• Protect cells from stress-related damage and cell death

• Support repair of small nerve fibers, which are the fibers most affected in many forms of neuropathy

Small fiber neuropathy is especially hard to treat, because these thin fibers carry pain and temperature signals and are easily damaged by diabetes, autoimmune disease, and other conditions.

What Do the Studies Say?

The human research so far is promising but early. Phase 2 clinical trials tested daily injections of ARA 290 over a few weeks in people with:

• Sarcoidosis-related small fiber neuropathy

• Type 2 diabetes with painful neuropathy

In these studies, participants reported improvements in neuropathic pain and symptom scores, and some measurements suggested improvement in small nerve fiber density in the cornea, which is used as a stand-in for nerve health. Several participants also showed better blood sugar control.

It is important to be realistic about these results:

• The trials were small and short

• Results varied from person to person

• There are no large Phase 3 trials and no long-term safety data

• ARA 290 is not an approved drug anywhere

A Word of Caution About Sourcing

Because ARA 290 is investigational, products sold online as "research peptides" are not regulated for purity, strength, or sterility. Injecting an unverified product carries real risks, including contamination, incorrect dosing, and unknown side effects. Anyone considering a peptide therapy should talk with a licensed healthcare provider and understand the current legal and regulatory status.

Supporting Nerve Health Today

While research on peptides like ARA 290 continues, there are well-established ways to support people with neuropathy:

• Getting blood sugar under good control if you have diabetes

• Checking for correctable causes such as B12 deficiency, thyroid problems, and medication effects

• Regular movement and appropriate foot care

• Acupuncture, which some studies suggest may help reduce neuropathic pain for some people

• Working with your physician on pain management options

The Bottom Line

ARA 290 is one of the more interesting investigational approaches to neuropathy because it aims to protect and repair nerves instead of just masking pain. But the evidence is still early, and it is not an approved treatment. If you are dealing with neuropathy, the best first step is a thorough evaluation to find the underlying cause and build a plan that fits you.

Have questions about neuropathy and your options? Contact our office to schedule a consultation